REG - Celadon Pharma. PLC - Notice of Results

Celadon PharmaceuticalsAnnouncement

12/09/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20220912:nRSL0161Za&default-theme=true

RNS Number : 0161Z  Celadon Pharmaceuticals PLC  12 September 2022

 

Celadon Pharmaceuticals Plc

 

("Celadon" or the "Company")

 

Notice of Results and Investor Presentation

 

LONDON, 12 September 2022: Celadon Pharmaceuticals Plc (AIM: CEL), a leading
UK based pharmaceutical company focused on the development and supply of
natural cannabis-based medicines, will announce its maiden results for the six
months ended 30 June 2022 on Thursday 29 September 2022.

 

Analyst Briefing: 9.00am, Thursday 29 September 2022

 

Management will host a virtual analyst presentation followed by a Q&A
session at 9.00am BST on Thursday 29 September 2022. Analysts wishing to join
should register their interest by contacting celadon@powerscourt-group.com
(mailto:celadon@powerscourt-group.com) .

 

Investor Presentation: 2.30pm, Thursday 29 September 2022

 

Management will be hosting a live presentation and Q&A session via the
online platform, Investor Meet Company, at 2.30pm BST on Thursday 29 September
2022.

 

The presentation is open to analysts and all existing and potential
shareholders. Questions can be submitted pre-event via the Investor Meet
Company dashboard up until 9.00am on Thursday 29 September 2022 or at any time
during the live presentation. Investors can sign up to Investor Meet Company
for free via:
https://www.investormeetcompany.com/celadon-pharmaceuticals-plc/register-investor
(https://www.investormeetcompany.com/celadon-pharmaceuticals-plc/register-investor)

 

Investors who already follow Celadon on the Investor Meet Company platform
will automatically receive an invitation to the event.

 

Enquiries:

 Celadon Pharmaceuticals Plc
 James Short                                               Via Powerscourt

 Arthur Wakeley

 Canaccord Genuity Limited (Nominated Adviser and Broker)
 Andrew Potts / Patrick Dolaghan / Bobbie Hilliam          +44 (0)20 7523 8000

 Powerscourt Group
 Sarah MacLeod / Nick Johnson / Sam Austrums /             +44 (0)20 7250 1446

 Ibrahim Khalil                                            celadon@powerscourt-group.com

 

About Celadon Pharmaceuticals Plc

Celadon Pharmaceuticals Plc is a UK based pharmaceutical company focused on
the research, cultivation, manufacturing, and supply of natural cannabis-based
medicines. Its primary focus is on improving quality of life for chronic pain
sufferers, as well as exploring the potential of cannabis-based medicines for
other conditions such as autism. Its 100,000 sq. ft UK facility comprises a
laboratory designed to meet GMP standards, and capacity for a large indoor
hydroponic growing facility that has received a Home Office License to legally
grow high-THC medicinal cannabis for the purpose of producing test batches of
cannabis oil to support its application to the MHRA. The Company's subsidiary,
LVL, owns a MHRA conditionally-approved cannabis trial using cannabis based
medicinal products to treat chronic pain in the UK.

 

For further information please visit our website www.celadonpharma.com
(http://www.celadonpharma.com)

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  NORBGGDCBBBDGDB